KDR and hepatocellular carcinoma: Sorafenib, a multi-kinase inhibitor of VEGF/VEGFR and RAF/MEK/ERK pathways that exhibits anti-angiogenic and anti-proliferative activities, is recommended as a standard first-line drug for patients with advanced-stage HCC.